The effects of PON1 gene Q192R variant on the development of uterine leiomyoma in Turkish patients

In Vivo

Volumn 29, Issue 2, 2015, Pages 243-246

  Attar, Rukset ^a   Atasoy, Hande ^a   Inal Gültekin, Güldal ^b   Timirci Kahraman, Özlem ^b   Güleç Yilmaz, Seda ^a   Dalan, Altay Burak ^a   Yildirim, Gazi ^a   Ergen, Arzu ^b   Isbir, Turgay ^a  

^a YEDITEPE UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Cancer; Ethnicity; Paraoxanase; PON 192; Uterine benign tumor

Indexed keywords

ADULT; ALLELE; ARTICLE; ARYLDIALKYLPHOSPHATASE GENE; CHI SQUARE TEST; CONTROLLED STUDY; FEMALE; FISHER EXACT TEST; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; QUALITY OF LIFE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUMOR VOLUME; TURK (PEOPLE); UTERUS MYOMA; AMINO ACID SUBSTITUTION; CASE CONTROL STUDY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; LEIOMYOMA; MIDDLE AGED; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TURKEY;

ARYLDIALKYLPHOSPHATASE; PON1 PROTEIN, HUMAN;

ADULT; ALLELES; AMINO ACID SUBSTITUTION; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LEIOMYOMA; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TURKEY;

EID: 84928170718     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Turan MC and Büyükbayrak EE: Myomalarda tedavi secenekleri. TJOD Uzmanlik Sonrasi Egitim Dergisi 8: 163-169, 2004.
2. Ekin M, Cengiz H, Öztürk E, Kaya C, Yasar L and Savan K: Genitourinary symptoms and their effects on quality of life in women with uterine myomas. Int Urogynecol J 25: 807-810, 2014.
3. Flake GP, Andersen J and Dixon D: Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 111(8): 1037-1054, 2003.
4. National Center for Biotechnology Information, http:// www.ncbi.nlm.nih.gov/gene/5444. (Accesed: December 2014)
5. Wysocka A, Cybulski M, Berbeć H, Wysokiński A, Stążka J and Zapolski T: Prognostic value of paraoxonase 1 in patients undergoing coronary artery bypass grafting surgery. Med Sci Monit 20: 594-600, 2014.
6. Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY and Goodman MT: Genetic polymorphisms in the paraoxonase 1 gene and risk of ovarian epithelial carcinoma. Cancer Epidemiol Biomarkers Prev 17(8): 2070-2077, 2008.
7. Ozturk O, Kaʇnici OF, Ozturk T, Durak H, Tuzuner BM, Kisakesen HI, Cakalir C and Isbir T: 192R Allele of Paraoxanase 1 (PON1) Gene as a New Marker for Susceptibility to Bladder Cancer. Anticancer Research 29: 4041-4046, 2009.
8. Arpaci A, Görmüş U, Dalan B, Berkman S and Isbir T. Investigation of PON1 192 and PON1 55 Polymorphisms in Ovarian Cancer Patients in Turkish Population. In Vivo 23: 421-424, 2009.
9. Aksoy-Sagirli P, Cakmakoʇlu B, Isbir T, Kaytan-Saʇlam E, Kizir A, Topuz E and Berkkan H: Paraoxonase-1 192/55 Polymorphisms and the Risk of Lung Cancer in a Turkish Population. Anticancer Res 31: 2225-2230, 2011.
10. Stevens VL, Rodriguez C, Pavluck AL, Thun MJ and Calle EE: Association of polymorphisms in the paraoxonase 1 gene with breast cancer incidence in the CPS-II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 15: 1226-1228, 2006.
11. Gallicchio L, McSorley MA, Newschaffer CJ, Huang HY, Thuita LW, Hoffman SC and Helzlsouer KJ: Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease. Cancer Detect Prev 31: 95-101, 2007.
12. Hussein YM, Gharib AF, Etewa RL and ElSawy WH: Association of L55M and Q192R polymorphisms in paraoxonase 1(PON1) gene with breast cancer risk and their clinical significance Mol Cell Biochem 351: 117-123, 2011.
13. Antognelli C, Mearini L, Talesa VN, Giannantoni A and Mearini E: Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. Prostate 63: 240-251, 2005.
14. Lee CH, Lee KY, Choe KH, Hong YC, Kim YD, Kang JW and Kim H: Effects of oxidative DNA damage induced by polycyclic aromatic hydrocarbons and genetic polymorphism of the paraoxonase-1 (PON1) gene on lung cancer. JPrev Med Pub Health 38: 345-350, 2005.
15. Kerridge I, Lincz L, Scorgie F, Hickey D, Granter N and Spencer A: Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. Br JHaematol 118: 477-481, 2002.
16. Lincz LF, Kerridge I, Scorgie FE, Bailey M, Enno A and Spencer A: Xenobiotic gene polymorphisms and susceptibility to multiple myeloma. Haematologica 89: 628-629, 2004.
17. Adkins S, Gan KN, Mody M and La Du BN: Molecular basis for the polymorphic forms of human serumparaoxonase/ arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52(3): 598-608, 1993.
18. Zhang Q, Ubago J, Li L, Guo H, Liu Y, Qiang W, Kim JJ, Kong B and Wei JJ: Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma. Cancer 120(20): 3165-3177, 2014.
19. Verit FF and Yucel O: Endometriosis, leiomyoma and adenomyosis: the risk of gynecologic malignancy. Asian Pac J Cancer Prev 14(10): 5589-5597, 2013.
20. Rowlands IJ, Nagle CM, Spurdle AB and Webb PM: Gynecological conditions and the risk of endometrial cancer. Gynecol Oncol 123: 537-541, 2011.
21. Flynn M, Jamison M, Datta S and Myers E: Health care resource for uterine fibroid tumors in the United States Michael. American Journal of Obstetrics and Gynecology 195: 955-964, 2006.
22. Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ and Segars JH: The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol 206(3): 211.e1-9, 2012.
23. Baird DD, Dunson DB, Hill MC, Cousins D and Schectman JM: High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 188: 100-107, 2000.
24. Catherino WH, Eltoukhi HM and Al-Hendy A: Racial and ethnic differences in the pathogenesis and clinical manifestations of uterine leiomyoma. Semin Reprod Med 31(5): 370-379, 2013.
25. Edwards TL, Michels KA, Hartmann KE and Velez Edwards DR: BET1L and TNRC6B associate with uterine fibroid risk among European Americans. Hum Genet 132(8): 943-953, 2013.
26. Shen Y, Ren ML, Xu J, Xu Q, Ding YQ, Wu ZC, Zhang HB, Huang XX and Cai YL: A multicenter case-control study on screening of single nucleotide polymorphisms in estrogen-metabolizing enzymes and susceptibility to uterine leiomyoma in han chinese. Gynecol Obstet Invest 77(4): 224-230, 2014.
27. Hakverdi S, Demirhan O, Tunc E, Inandiklioglu N, Uslu IN, Gungoren A, Erdem D and Hakverdi AU: Chromosome imbalances and alterations in the p53 gene in uterine myomas from the same family members: familial leiomyomatosis in Turkey. Asian Pac J Cancer Prev 14(2): 651-658, 2013.
28. Cha PC, Takahashi A, Hosono N, Low SK, Kamatani N, Kubo M and Nakamura Y: A genome-wide association study identifies three loci associated with susceptibility to uterine fibroids. Nat Genet 43(5): 447-450, 2011.
29. Fishchuk LE and Gorovenko NG. Genetic polymorphisms of the renin-angiotensin system in breast cancer patients. Exp Oncol 35(2): 101-104, 2013.
30. Risau W. Mechanisms of angiogenesis. Nature 386(6626): 671-674, 1997.
31. Di Lieto A, De Falco M, Pollio F, Mansueto G, Salvatore G, Somma P, Ciociola F, De Rosa G and Staibano S: Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue- treated women with uterine myomas. J Soc Gynecol Investig 12: 123-128, 2005. (abstract)
32. Tal R and Segars JH. The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy. Hum Reprod Update 20(2): 194-216, 2014.
33. Ateş O, Demirturk F, Toprak M and Sezer S: Polymorphism of catechol-o-methyltransferase and uterine leiomyoma. Mol Cell Biochem 375(1-2): 179-183, 2013.